St. John’s wort vs. Paxil
This article was originally published in The Tan Sheet
Executive Summary
Dr. Willmar Schwabe Pharmaceuticals' St. John's wort extract WS 5570 is "at least as effective as" GlaxoSmithKline's antidepressant Paxil (paroxetine) "over six weeks of acute treatment in out-patients with moderate or severe unipolar major depression," a Schwabe-funded study finds. The results "support the use of [St. John's wort] as an alternative to standard antidepressants in moderate to severe depression, especially as well-tolerated," A. Szegedi, Charite Universitatsmedizin, Berlin, et al., report in the Feb. 11 British Medical Journal. The study's 251 participants, who ranged in age from 18-70, were randomized to either 900 mg/day WS 5570 or 20 mg paroxetine once daily for six weeks. Response to treatment was measured by change in score on the Hamilton scale from baseline to day 42. The lead author has received consultancy fees from the firm, and two other study authors are employees of Schwabe...
You may also be interested in...
St. John’s Wort “Significantly More Effective” Than Prozac, Study Finds
St. John's wort is more effective at treating major depressive disorder (MDD) than fluoxetine (Eli Lilly's Prozac), according to a study published in the October Journal of Clinical Psychopharmacology.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.